Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Clinicopathological Correlation of BRCA1 Status in High‑Grade Serous Ovarian Carcinoma via IHC and NGS.

Created on 29 Sep 2026

Authors

Fathurrahman Muiz, Rina Masadah, Berti J Nelwan, Upik A Miskad, Ni Ketut Sungowati, Cahyono Kaelan, Andi Alfian Zainuddin, Syahrul Rauf, Nugraha Utama Pelupessy, Amalia Yamin, Amalia Mulia Utami

Published in

Asian Pacific journal of cancer prevention : APJCP. Volume 27. Issue 9. Pages 3213-3220. Sep 01, 2026. Epub Sep 01, 2026.

Abstract

High-grade serous ovarian carcinoma (HGSOC) is the most aggressive subtype of epithelial ovarian cancer and is frequently associated with BRCA1 dysfunction. This study aimed to evaluate the clinicopathological correlation of BRCA1 expression and mutation status assessed by immunohistochemistry (IHC) and next-generation sequencing (NGS) with the Whole Exome Sequencing (WES) approach.
A retrospective observational study was conducted on thirty-six formalin-fixed paraffin-embedded HGSOC samples. BRCA1 expression was evaluated by IHC using a 10% nuclear staining cutoff. BRCA1 mutation profiling was performed using NGS with a whole-exome sequencing (WES) approach. Clinicopathological variables were analyzed using Fisher's exact test.
Abnormal BRCA1 expression was observed in 11.1% of cases, while BRCA1 mutations were detected in 27.8%. Most mutations were somatic (70%) and predominantly loss-of-function variants (90%). A significant association was found between abnormal BRCA1 expression and younger age (p = 0.023), whereas no association was observed with other clinicopathological parameters.
BRCA1 expression loss in HGSOC is associated with younger patient age. The discordance between IHC and mutation status highlights the complementary role of protein expression and molecular testing. A combined IHC-NGS approach may improve the identification of BRCA1 deficiency and support therapeutic decision-making, particularly in the context of targeted therapy.

PMID:
42808387
Bibliographic data and abstract were imported from PubMed on 29 Sep 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 13
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement